BlackRock’s Avadel Pharmaceuticals AVDL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-7,041,102
| Closed | -$152M | – | 5689 |
|
|
2025
Q4 | $152M | Buy |
7,041,102
+67,444
| +1% | +$1.31M | ﹤0.01% | 1860 |
|
|
2025
Q3 | $106M | Buy |
6,973,658
+170,259
| +3% | +$2.22M | ﹤0.01% | 2065 |
|
|
2025
Q2 | $60.2M | Buy |
6,803,399
+1,349,873
| +25% | +$11.9M | ﹤0.01% | 2339 |
|
|
2025
Q1 | $42.7M | Buy |
5,453,526
+14,118
| +0.3% | +$118K | ﹤0.01% | 2457 |
|
|
2024
Q4 | $57.2M | Buy |
5,439,408
+182,404
| +3% | +$2.22M | ﹤0.01% | 2373 |
|
|
2024
Q3 | $68.9M | Buy |
5,257,004
+440,261
| +9% | +$6.71M | ﹤0.01% | 2284 |
|
|
2024
Q2 | $67.7M | Buy |
4,816,743
+4,740,301
| +6,201% | +$77.3M | ﹤0.01% | 2250 |
|
|
2024
Q1 | $1.29M | Sell |
76,442
-5,090
| -6% | -$75.8K | ﹤0.01% | 4123 |
|
|
2023
Q4 | $1.15M | Buy |
81,532
+3,047
| +4% | +$35.8K | ﹤0.01% | 4218 |
|
|
2023
Q3 | $808K | Buy |
78,485
+25,101
| +47% | +$336K | ﹤0.01% | 4299 |
|
|
2023
Q2 | $880K | Buy |
53,384
+6,185
| +13% | +$80.4K | ﹤0.01% | 4322 |
|
|
2023
Q1 | $432K | Buy |
47,199
+8,881
| +23% | +$73K | ﹤0.01% | 4563 |
|
|
2022
Q4 | $274K | Buy |
38,318
+4,249
| +12% | +$29.8K | ﹤0.01% | 4762 |
|
|
2022
Q3 | $171K | Buy |
34,069
+5,299
| +18% | +$29.2K | ﹤0.01% | 5012 |
|
|
2022
Q2 | $70K | Sell |
28,770
-7,936
| -22% | -$32.6K | ﹤0.01% | 5338 |
|
|
2022
Q1 | $251K | Buy |
36,706
+6,782
| +23% | +$46.6K | ﹤0.01% | 5048 |
|
|
2021
Q4 | $242K | Buy |
29,924
+9
| +0% | +$82 | ﹤0.01% | 5066 |
|
|
2021
Q3 | $293K | Buy |
29,915
+5,337
| +22% | +$42K | ﹤0.01% | 4890 |
|
|
2021
Q2 | $165K | Sell |
24,578
-484,706
| -95% | -$3.85M | ﹤0.01% | 4935 |
|
|
2021
Q1 | $4.6M | Sell |
509,284
-74,384
| -13% | -$601K | ﹤0.01% | 3979 |
|
|
2020
Q4 | $3.9M | Buy |
+583,668
| New | +$3.65M | ﹤0.01% | 3802 |
|
|
2018
Q4 | – | Sell |
-483,369
| Closed | -$2.12M | – | 4951 |
|
|
2018
Q3 | $2.12M | Sell |
483,369
-4,769
| -1% | -$25.8K | ﹤0.01% | 3756 |
|
|
2018
Q2 | $2.99M | Sell |
488,138
-24,313
| -5% | -$171K | ﹤0.01% | 3618 |
|
|
2018
Q1 | $3.73M | Sell |
512,451
-49,888
| -9% | -$439K | ﹤0.01% | 3504 |
|
|
2017
Q4 | $4.61M | Sell |
562,339
-20,915
| -4% | -$196K | ﹤0.01% | 3469 |
|
|
2017
Q3 | $6.12M | Buy |
583,254
+57,516
| +11% | +$549K | ﹤0.01% | 3403 |
|
|
2017
Q2 | $5.8M | Sell |
525,738
-17,986
| -3% | -$181K | ﹤0.01% | 3431 |
|
|
2017
Q1 | $5.26M | Buy |
+543,724
| New | +$5.44M | ﹤0.01% | 3367 |
|
|
2015
Q4 | – | Sell |
-1,300
| Closed | -$21K | – | 3433 |
|
|
2015
Q3 | $21K | Buy |
+1,300
| New | +$28.6K | ﹤0.01% | 2350 |
|
Other funds holding AVDL
BlackRock's AVDL Position: Q1 2026 in Review
BlackRock sold out of Avadel Pharmaceuticals (AVDL) in Q1 2026, closing a stake of 7,041,102 shares — an estimated $152M sold.
BlackRock first reported a position in AVDL in Q3 2015 and held it in 29 quarters. The position peaked at $152M in Q4 2025. 2 funds tracked by Wall St. Rank hold AVDL as of Q1 2026.
- BlackRock reported no remaining Avadel Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- BlackRock sold 7,041,102 Avadel Pharmaceuticals shares in Q1 2026, an estimated $152M.
- BlackRock first reported a position in Avadel Pharmaceuticals in Q3 2015 and held it in 29 quarters.
- BlackRock's Avadel Pharmaceuticals position peaked at $152M in Q4 2025.
- 2 funds tracked by Wall St. Rank held Avadel Pharmaceuticals as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.